
The REVIVED-BCIS2 trial investigated the impact of percutaneous coronary intervention (PCI) on patients with ischemic left ventricular dysfunction, exploring the prognostic value of myocardial viability testing. Among 610 participants, viability testing did not predict PCI benefit. The extent of nonviable myocardium, not viable myocardium, correlated with event-free survival and left ventricular function improvement. These findings challenge the utility of viability testing in identifying PCI candidates for ischemic cardiomyopathy.
Like
Save
Share